|
|
 |
|
Viewing report
|
|
|
|
Market and Product Forecasts: Targeted Cancer Therapies - Trend towards personalized medicine will lead to market fragmentation
Datamonitor, Oct 2011, Pages: 100
The targeted therapies class boasts several of the top-selling anticancer brands, and has fueled most of the recent rapid growth of the oncology market as a whole. In the next decade, several blockbuster targeted therapies will undergo patent expiries and the market will become more fragmented as new targeted therapies are developed for niche populations.
Features and benefits
- Sales forecasts of targeted cancer therapy brands over the period 2010-20 in the seven major pharmaceutical markets.
- Includes an overview of the overall targeted therapies market as well as country specific and brand specific forecasts.
- Analysis of the impact of generics and biosimilars on the marketed targeted cancer therapy brands over the forecast period 2010-20
- Analysis of pharmacoeconomic constraints likely to affect sales growth in the seven major pharmaceutical markets.
Highlights
- Datamonitor forecasts the currently marketed targeted cancer therapies to achieve collective sales of $34.5bn by 2017 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK), growing at a compound annual growth rate (CAGR) of 4.0% from 2010 to 2017.
- Datamonitor forecasts the sales value of currently marketed targeted cancer therapies will contract at a CAGR of -3.5% from 2017 to 2020, owing to patent expiries of some key brands in this class.
- Monoclonal antibodies will remain the dominant class in the targeted therapies market accounting for 62% of the sales of currently marketed targeted cancer therapies by 2020.
Your key questions answered
- Access Datamonitor’s company reported sales based market forecasts for targeted cancer therapies in the US, Japan and five major EU markets.
- Analyze the sales forecasts in each of the seven major markets and for each of the targeted cancer therapy brands across the forecast period 2010-20.
- Report is accompanied by a PowerPoint presentation and Excel deliverable showing the transparent methodology and forecasting assumptions.
|
|
|
|
